# Nigella 5 in the Treatment of SARS COV2 (COVID-19)

> **NCT04914767** · PHASE1 · COMPLETED · sponsor: **Hôpital Universitaire Sahloul** · enrollment: 500 (actual)

## Conditions studied

- SARS-CoV2 Infection

## Interventions

- **DRUG:** Nigella
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04914767
- **Lead sponsor:** Hôpital Universitaire Sahloul
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2021-10-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2022-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04914767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04914767, "Nigella 5 in the Treatment of SARS COV2 (COVID-19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04914767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*